Jacob Odeberg
About Jacob Odebergs research:
Developments within healthcare are heading towards what is known as personalised medicine. This requires disease-specific biomarker-based analyses for a better and faster way of identifying which patients will or will not respond to a certain treatment, predicting which patients will experience serious side-effects, making early diagnoses or identifying which individuals are at a greater risk of becoming ill in the future.
Sweden has unique healthcare registers and biobanks that are available for research. Together with the world’s largest resource of recognition reagents (antibodies) against the various human proteins generated within the Human Protein Atlas (HPA) project at KTH – financed by an SEK 900 million grant from the Knut and Alice Wallenberg Foundation – Jacob Odeberg and his group can use affinity proteomics to screen for new biomarkers in collected biobanks, and can develop new methods for the clinical validation and implementation of biomarkers within routine healthcare. This is done within a multidisciplinary group with backgrounds in technology, clinical practice and biomedicine.
Disease-specific biomarkers that make personalised medicine possible lead to improved patient safety and more cost-effective care for society as a whole.